Thomas B. Voigt

Mr. Thomas B. Voigt

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in American Journal of Physiology-Cell Physiology
Verified
Journal Article
Closed access
PDF file
BGBlas A. Guigni
Blas A. Guigni
DCDamien M. Callahan
Damien M. Callahan
TTTimothy W. Tourville
Timothy W. Tourville
MMMark S. Miller
Mark S. Miller
BFBrad Fiske
Brad Fiske
MTMichael J. Toth
Michael J. Toth
How breast cancer and its treatments affect skeletal muscle is not well defined. To address this question, we assessed skeletal muscle structure and protein expression in 13 women who were diagnosed with breast cancer and receiving adjuvant chemotherapy following tumor resection and 12 nondiseased controls. Breast cancer patients showed reduced single-muscle fiber cross-sectional area and fractional content of subsarcolemmal and intermyofibrillar mitochondria. Drugs commonly used in breast cancer patients (doxorubicin and paclitaxel) caused reductions in myosin expression, mitochondrial loss, and increased reactive oxygen species (ROS) production in C2C12 murine myotube cell cultures, supporting a role for chemotherapeutics in the atrophic and mitochondrial phenotypes. Additionally, concurrent treatment of myotubes with the mitochondrial-targeted antioxidant MitoQ prevented chemotherapy-induced myosin depletion, mitochondrial loss, and ROS production. In patients, reduced mitochondrial content and size and increased expression and oxidation of peroxiredoxin 3, a mitochondrial peroxidase, were associated with reduced muscle fiber cross-sectional area. Our results suggest that chemotherapeutics may adversely affect skeletal muscle in patients and that these effects may be driven through effects of these drugs on mitochondrial content and/or ROS production.

13 November 2019 in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Verified
Journal Article
Open access
PDF file
CSChad R Straight
Chad R Straight
TVThomas B. Voigt
Thomas B. Voigt
AJAnudeep V Jala
Anudeep V Jala
JCJohn D Chase
John D Chase
OROlivia R Ringham
Olivia R Ringham
MMMark S Miller
Mark S Miller
Increased adiposity is associated with reduced skeletal muscle function in older adults, but the mechanisms underlying this relationship remain unclear. To explore whether skeletal muscle properties track with adiposity, whole-muscle, cellular, and molecular function were examined in relation to adiposity measured at various anatomical levels in healthy older (60–80 years) men and women. Although women had greater absolute and relative body and thigh fat than men, quadriceps muscle attenuation, an index of intramuscular lipid content, was similar between sexes. At the whole-muscle level, greater quadriceps attenuation was associated with reduced knee extensor function in women, but not men. In women, decreased myosin heavy chain I and IIA fiber-specific force was associated with higher intramuscular lipid content, which may be explained, in part, by the reduced myofilament lattice stiffness found in myosin heavy chain IIA fibers. Longer myosin attachment times in myosin heavy chain I fibers from men and women were associated with greater amounts of adipose tissue, suggesting that fat deposits lead to slower myosin–actin cross-bridge kinetics. Our results indicate greater quantities of adipose tissue alter myofilament properties and cross-bridge kinetics, which may partially explain the adiposity-induced decrements in single-fiber and whole-muscle function of older adults, especially women.

29 March 2023 in Science Translational Medicine
Verified
Journal Article
Open access
MRMichael J. Ricciardi
Michael J. Ricciardi
LRLauren N. Rust
Lauren N. Rust
NPNuria Pedreño-Lopez
Nuria Pedreño-Lopez
SYSofiya Yusova
Sofiya Yusova
SBSreya Biswas
Sreya Biswas
Benjamin BurwitzBenjamin Burwitz
Benjamin Burwitz
Yellow fever virus (YFV) is a reemerging global health threat, driven by several factors, including increased spread of the mosquito vector and rapid urbanization. Although a prophylactic vaccine exists, vaccine hesitancy, supply deficits, and distribution difficulties leave specific populations at risk of severe YFV disease, as evidenced by recent outbreaks in South America. To establish a treatment for patients with severe YFV infection, we tested 37 YFV-specific monoclonal antibodies isolated from vaccinated humans and identified two capable of potently neutralizing multiple pathogenic primary YFV isolates. Using both hamster and nonhuman primate models of lethal YFV infection, we demonstrate that a single administration of either of these two potently neutralizing antibodies during acute infection fully controlled viremia and prevented severe disease and death in treated animals. Given the potential severity of YFV-induced disease, our results show that these antibodies could be effective in saving lives and fill a much-needed void in managing YFV cases during outbreaks.

6 September 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
FZFangzhu Zhao
Fangzhu Zhao
ZBZachary T. Berndsen
Zachary T. Berndsen
NPNuria Pedreño-Lopez
Nuria Pedreño-Lopez
ABAlison Burns
Alison Burns
JAJoel D. Allen
Joel D. Allen
DSDevin Sok
Devin Sok
SIVmac239 infection of macaques is a favored model of human HIV infection. However, the SIVmac239 envelope (Env) trimer structure, glycan occupancy, and the targets and ability of neutralizing antibodies (nAbs) to protect against SIVmac239 remain unknown. Here, we report the isolation of SIVmac239 nAbs that recognize a glycan hole and the V1/V4 loop. A high-resolution structure of a SIVmac239 Env trimer-nAb complex shows many similarities to HIV and SIVcpz Envs, but with distinct V4 features and an extended V1 loop. Moreover, SIVmac239 Env has a higher glycan shield density than HIV Env that may contribute to poor or delayed nAb responses in SIVmac239-infected macaques. Passive transfer of a nAb protects macaques from repeated intravenous SIVmac239 challenge at serum titers comparable to those described for protection of humans against HIV infection. Our results provide structural insights for vaccine design and shed light on antibody-mediated protection in the SIV model.

1 September 2022 in Journal of Applied Physiology
Verified
Journal Article
Open access
PDF file
MTMichael J. Toth
Michael J. Toth
PSPatrick D. Savage
Patrick D. Savage
TVThomas B. Voigt
Thomas B. Voigt
BABradley M. Anair
Bradley M. Anair
JBJanice Y. Bunn
Janice Y. Bunn
NNNathaniel J. Nelms
Nathaniel J. Nelms
We report the first evaluation of the effects of total knee arthroplasty (TKA) on skeletal muscle at the cellular and subcellular levels. We found marked effects of TKA to cause skeletal muscle fiber atrophy and contractile dysfunction in older adults, as well as molecular mechanisms underlying impaired contractility. Our results reveal profound effects of TKA on muscle fiber size and intrinsic contractility early after surgery that may contribute to functional disability.

18 May 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
MRMichael J. Ricciardi
Michael J. Ricciardi
LRLauren N. Rust
Lauren N. Rust
NPNuria Pedreño-Lopez
Nuria Pedreño-Lopez
SYSofiya Yusova
Sofiya Yusova
SBSreya Biswas
Sreya Biswas
Benjamin BurwitzBenjamin Burwitz
Benjamin Burwitz
Few countermeasures to treat Yellow Fever virus (YFV) infection are under development, because vaccines have helped to limit new infections. Unfortunately, vaccine hesitancy, supply deficits, and a paucity of therapeutic options have left individuals at risk. Here, we tested potent YFV-specific neutralizing monoclonal antibodies in rodents and non-human primates. We administered antibodies during acute pathogenic YFV infection and demonstrate that we can prevent severe disease and death. Given the severity of YFV-induced disease, our results show that these antibodies could be effective in saving lives and fill a much-needed void in managing Yellow Fever cases during outbreaks around the world. One Sentence Summary: Therapeutic monoclonal antibodies prevent death from YFV infection.